• Aurinia Pharmaceuticals’ net income rose to $31.7 million for the three months ended September 30, 2026.
• Total revenue climbed 14% year over year to $83.7 million for the same period.
• Operating cash flow increased 46% year over year to $131.5 million for the nine months ended September 30, 2026.
• Aurinia initiated the Phase 4 PRESERVE study investigating LUPKYNIS combined with biologic agents in patients with lupus nephritis.
• The company raised its 2026 total revenue guidance to $325 million–$330 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261030369613) on October 30, 2026, and is solely responsible for the information contained therein.